Pharmacy India
Pharmacy India is your ultimate destination for pharmacy exam preparation and career advancement. Discover top-notch study materials, daily quizzes, and expert courses for pharmacy exams like RRB Pharmacist, GPAT, and NIPER JEE, D.Pharma Exit Exam, etc.
Unlock a world of opportunities with free pharmacist registration on Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana’s website! If you’re a qualified pharmacist, this is your chance to become an integral part of a revolutionary initiative aimed at making quality healthcare accessible to all.
डिप्लोमा इन फार्मेसी एग्जिट एग्जामिनेशन (DPEE) का उद्देश्य यह सुनिश्चित करना है कि राज्य फार्मेसी काउंसिल के साथ फार्मासिस्ट के रूप में पंजीकरण के लिए आवेदन करने वाले उम्मीदवार ने फार्मेसी शिक्षा और डिप्लोमा इन फार्मेसी (D.Pharm) पाठ्यक्रम में एक व्यापक व्यावहारिक प्रशिक्षण कार्यक्रम प्राप्त किया है। शिक्षा विनियम, 2020 या विनियम जो फार्मेसी अधिनियम, 1948 की धारा 12 के तहत फार्मेसी काउंसिल ऑफ इंडिया द्वारा अनुमोदित संस्थान में समय-समय पर लागू हो सकते हैं और दवाओं के वितरण और फार्मेसी अभ्यास के अन्य क्षेत्रों में मुख्य दक्षता हासिल कर सकते हैं।
Following up on our earlier circulars, we are glad to notify you of the impending Diploma in Pharmacy (D. Pharm) Exit Examination, which is set for July–September 2024 for the 2022–2024 academic year. This test is an important part of…
In a recent plea to the director general of the Andhra Pradesh Drugs Control Administration (APDCA), the Andhra Pradesh Pharmacists Confederation (APPC) brought attention to a worrying pattern of the state’s lacklustre enforcement of laws against retail drug stores that break the law. The President of the APPC, Dr. Singanamala Suman Modi, has stressed in a lengthy letter how urgently the DCA must step in to address the widespread illegal practices in the pharmaceutical industry.
A significant directive impacting the production and marketing of common cold fixed dosage combinations (FDC) including chlorpheniramine maleate IP 2 mg and phenylephrine HCL IP 5 mg per millilitre drops has been issued by the Drugs Controller General of India (DCGI) in a recent development. Prompted by suggestions from a Subject Expert Committee (SEC) focused on pulmonary issues, the directive requires manufacturers to advise against using this combination in children younger than four years old on the label, package insert, and promotional materials.
The Drugs Consultative Committee (DCC) has recently undertaken a comprehensive examination into the potential misuse of opioid pain-relief medicine tapentadol and the anticonvulsant and analgesic drug pregabalin. This blog post delves into the committee’s decisions and considerations, shedding light on the recommendations for potential control measures on the sales of these drugs in the market.
In a recent development, the Union health ministry’s draft National Pharmacy Commission (NPC) Bill 2023 faces opposition from the Student Pharmacists Rights Committee (SPRC) in Maharashtra. The SPRC has passed a resolution urging the Union government to reconsider its move to create the NPC, emphasizing the importance of retaining the Pharmacy Council of India (PCI).
In a significant move towards global vaccine quality benchmarks, the Drugs Consultative Committee (DCC) has called upon all Indian states to provide crucial data on vaccine manufacturing and sales. The World Health Organization (WHO) mandates this data for its Global Benchmarking Tool (GBT) assessment, a prerequisite for UN agencies to procure vaccines from Indian manufacturers.
In a significant stride towards transparency and corruption prevention in drug regulation, the central drug regulator is gearing up to introduce a digital platform. The recent Drugs Consultative Committee (DCC) meeting, chaired by the Drugs Controller General (India) Dr Rajeev Singh Raghuvanshi, highlighted the imperative need for Standard Operating Procedures (SOPs) for videography in procedures related to sampling and testing.
In a decisive move to tackle quality issues in pharmaceutical excipients, the Drugs Consultative Committee (DCC) of the Union health ministry has recommended stringent measures. The recent meeting, chaired by Drugs Controller General of India (DCGI) Dr Rajeev Singh Raghuvanshi, emphasized the necessity of adhering to the Drugs and Cosmetics Act for the use of only pharma-grade excipients.
This will close in 0 seconds
This will close in 0 seconds
